Dr. Beaulieu currently leads Peptomyc’s pipeline expansion activities and coordinates the chemistry, manufacturing and controls as well as biomarker discovery activities related to Peptomyc’s lead asset, OMO-103.
Marie-Eve gained extensive experience in pharmaceutical development of therapeutic proteins and peptides through her previous work with the pharmaceutical industry and the preclinical development of OMO-103. After having established from scratch Peptomyc’s Protein Platform and discovered the cell penetrating potential of Omomyc, Marie-Eve helped building the company strategy, achieve successful fundraising (public >5MEur and private ~30MEur) and reach key development milestones for OMO-103 (successful clinical trial approval by AEMPS and BfArm by leading IMPD and IB preparation).
Marie-Eve has co-authored 4 patent applications, 28 peer-reviewed publications and 4 book chapters. She awarded several competitive fellowships (CREFSIP scholarship, MITACS (postdoc fellow at Theratechnologies Inc., Montreal, Canada) and FRSQ postdoctoral award from the Quebec government.
Work
Peptomyc S.L.
Spain
→
Vall d'Hebron Institute of Oncology
Spain
→
Education
Université de Sherbrooke Faculté de Médecine et des Science de la Santé
Canada
→
Ph.D.
Publications
The Structural Determinants of GPCR Binding and Activation: Insights from Mutagenesis and Molecular Modeling Studies of the Human Angiotensin II Type 1 (hAT1) Receptor
Understanding Biology Using Peptides
other
Photolabeling with N-Terminal Urotensin II Photoprobes Identifies Methionine 288 of Rat Urotensin Receptor as a Contact Point
Understanding Biology Using Peptides
other
Structure Determination of the Human Angiotensin II Receptor Type 1 by the Methionine Proximity Assay
Understanding Biology Using Peptides
other
Data from MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding
preprint
Supplementary Data from MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding
preprint
Supplementary Data from MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding
preprint
Data from MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding
preprint
MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding
Cancer Research Communications
journal-article
Integrated requirement of non-specific and sequence-specific DNA binding in Myc-driven transcription.
The EMBO journal
journal-article
The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets.
Life science alliance
journal-article
MYC, MYCL, and MYCN as therapeutic targets in lung cancer
Expert Opinion on Therapeutic Targets
journal-article
Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein.
Cells
journal-article
Bioactive cell penetrating peptides and proteins in cancer: a bright future ahead.
Current opinion in pharmacology
journal-article
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
Science Translational Medicine
journal-article
Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies.